Founded in 2017, RubrYc Therapeutics, Inc. integrates massively parallel in silico simulation and empirical analyses of protein structures to address long-standing challenges in biotherapeutic discovery. In therapeutic antibody discovery, epitopes matter. Our platform enables a non-conventional approach that uniquely enriches discovery campaigns with therapeutic antibody candidates that are on target, on epitope, and optimized for the prescribed mode of action. RubrYc Therapeutics emerged as a spin-out from HealthTell, Inc. in April 2018. RubrYc has partnered with Third Point Ventures, iCarbonX, Paladin Capital, and Vital Venture Capital to complete its Series A financing. To date, the RubrYc team has also engaged 2 of the top 20 global biopharmaceutical companies in collaborations. RubrYc Therapeutics is located in San Carlos, CA, and currently has 10 employees.
Company HQ State:
Company HQ Country:
Main Therapeutic Focus:
Lead Product in Development:
Development Phase of Primary Product:
Number Of Unlicensed Products (For Which You Are Seeking Partners):